These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 7892554)
1. [High-dose chemotherapy with hematopoietic salvage in patients with breast cancer]. Perey L; Leyvraz S Praxis (Bern 1994); 1995 Mar; 84(9):259-63. PubMed ID: 7892554 [TBL] [Abstract][Full Text] [Related]
2. [High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy]. Derigs HG; Huber C; Mahlke M; Kolbe K Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):190-7. PubMed ID: 8682284 [TBL] [Abstract][Full Text] [Related]
3. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Myers SE; Mick R; Williams SF Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470 [TBL] [Abstract][Full Text] [Related]
5. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma]. Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324 [TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638 [TBL] [Abstract][Full Text] [Related]
7. [High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors]. Lotz JP; Pene F; Bouleuc C; André T; Gligorov J; Avenin D; Esteso A; Bellaiche A; Macovei C; Merad Z; Laadem A; Vanica R; Izrael V Contracept Fertil Sex; 1996 Apr; 24(4):307-18. PubMed ID: 8704806 [TBL] [Abstract][Full Text] [Related]
8. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059 [TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618 [TBL] [Abstract][Full Text] [Related]
10. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327 [TBL] [Abstract][Full Text] [Related]
11. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731 [TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Brockstein BE; Williams SF Stem Cells; 1996 Jan; 14(1):79-89. PubMed ID: 8820954 [TBL] [Abstract][Full Text] [Related]
14. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174 [TBL] [Abstract][Full Text] [Related]
15. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605 [TBL] [Abstract][Full Text] [Related]
17. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837 [TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
20. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]